As European markets experience a positive uptick, with the STOXX Europe 600 Index rising by 1.91% amid easing geopolitical tensions and corporate earnings reports, investors are closely watching dividend stocks for potential stability and income in an uncertain economic climate. A good dividend stock in this environment is typically characterized by consistent payouts and strong financial health, offering a reliable income stream even as broader market conditions fluctuate.

Italian prosecutors are investigating allegations of market rigging and obstruction of supervisory activities related to MPS’s recent acquisition of Mediobanca.

The €13.5bn takeover of Mediobanca was launched in January and completed in September.

As European markets rally, with the STOXX Europe 600 Index reaching record levels and major indices like Germany’s DAX and France’s CAC 40 showing strong gains, investors are increasingly focusing on dividend stocks as a way to capitalize on favorable market conditions. In this environment, a good dividend stock is often characterized by its ability to offer consistent yields while benefiting from positive economic sentiment and expectations for lower borrowing costs.

Caltagirone (BIT:CALT) experienced a price move of 16% over the past month. This uptick occurred alongside broader market trends, such as record highs in both the S&P 500 and Nasdaq, which were buoyed by lower-than-expected inflation data. The market's upward trajectory, marked by increasing enthusiasm for tech and AI-driven stocks, offered a supportive backdrop for Caltagirone's performance. Though specific events relating to Caltagirone's price movement were not identified, the overall...

If you are weighing your next move with Banca IFIS, you are not alone. After all, the stock has served up a mix of intrigue and promise this year, catching plenty of attention across the financial landscape. In the past week, the share price edged down just 0.8%, but zoom out a bit and the bigger story comes into focus. The stock is up 4.1% over the past month, 9.2% year to date, and a striking 20.5% over the past twelve months. Stretch that time frame further, and Banca IFIS has rewarded...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.